A Phase 1 interventional study of Selpercatinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-18.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to determine how safe and how well tolerated selpercatinib is when given as oral doses to healthy participants. The study will also assess how fast selpercatinib gets into the blood stream and how long it takes the body to remove it. The study will last up to about 6 weeks, inclusive of screening period.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single oral dose of 320 mg selpercatinib on Day 1, preceded by an overnight fast of at least 10 hours, followed by a fast from food (not including water) for at least 4 hours post dose.
Drug: Selpercatinib
Participants received a single oral dose of 640 mg selpercatinib on Day 1, preceded by an overnight fast of at least 10 hours, followed by a fast from food (not including water) for at least 4 hours post dose.
Drug: Selpercatinib
Participants received a single oral dose of 720 mg selpercatinib on Day 1, preceded by an overnight fast of at least 10 hours, followed by a fast from food (not including water) for at least 4 hours post dose.
Drug: Selpercatinib
Administered orally.
Also known as: LY3527723, LOXO-292
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.
Time frame: Baseline up to Day 8
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
PK: AUC0-t is calculated using the linear trapezoidal with linear interpolation method.
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
PK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib
PK: AUC0-24 was calculated using the linear trapezoidal with linear interpolation method.
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours postdose
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib
PK: AUC0-inf was calculated as AUC0-inf = AUC0-t + (Clast/Kel) where Clast is the last observed/measured concentration and Kel is the apparent terminal elimination rate constant, which represents the fraction of drug eliminated per unit time.
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib
PK: Percent of AUC0-inf extrapolated was calculated as (1-AUC0-t/AUC0-inf) \*100.
Time frame: Predose -168 hours post dose
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib
PK: CL/F was calculated as Dose/(AUC0-inf).
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
PK: Maximum Observed Concentration (Cmax) of Selpercatinib
PK: Cmax was taken directly from bioanalytical data.
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
PK: Time to Reach Cmax (Tmax) of Selpercatinib
PK: Tmax was time to reach Cmax. If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value taken from clinical database as the difference in the time of administration and the time of the blood draw which is associated with the Cmax.
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
PK: Apparent First-order Terminal Elimination Rate Constant (Kel) of Selpercatinib
PK: Apparent terminal elimination rate constant; represents the fraction of drug eliminated per unit time calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations).
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
PK: Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Selpercatinib
PK: Vz/F calculated as Dose/(AUC0-inf x Kel).
Time frame: Predose (within 30 minutes), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours postdose
| Milestone | 320 Milligram (mg) Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib |
|---|---|---|---|
| Started | 6 | 6 | 6 |
| Received at least one dose of study drug | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 |
Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.
| participants | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib |
|---|---|---|---|
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | 0 | 0 | 0 |
PK: AUC0-t is calculated using the linear trapezoidal with linear interpolation method.
| nanogram*hour per milliliter (ng*h/ mL) | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib |
|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib | 35900 ± 59.7 | 50460 ± 46.5 | 60960 ± 50.7 |
PK: AUC0-24 was calculated using the linear trapezoidal with linear interpolation method.
| ng*h/ mL | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib |
|---|---|---|---|
| PK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib | 21280 ± 79.8 | 30680 ± 50.5 | 36450 ± 58.3 |
PK: AUC0-inf was calculated as AUC0-inf = AUC0-t + (Clast/Kel) where Clast is the last observed/measured concentration and Kel is the apparent terminal elimination rate constant, which represents the fraction of drug eliminated per unit time.
| nanogram*hour per milliliter (ng*h/ mL) | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib |
|---|---|---|---|
| PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib | 36080 ± 59.7 | 50770 ± 46.7 | 61380 ± 50.7 |
PK: Percent of AUC0-inf extrapolated was calculated as (1-AUC0-t/AUC0-inf) \*100.
| percentage | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib |
|---|---|---|---|
| PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib | 0.5159 ± 0.44688 | 0.6238 ± 0.29008 | 0.6869 ± 0.29427 |
PK: CL/F was calculated as Dose/(AUC0-inf).
| Liters per Hour (L/h) | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib |
|---|---|---|---|
| PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib | 10.16 ± 6.3442 | 13.62 ± 5.5060 | 12.79 ± 5.2828 |
PK: Cmax was taken directly from bioanalytical data.
| nanograms per milliliter (ng/mL) | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib |
|---|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of Selpercatinib | 2282 ± 88.6 | 3316 ± 56.3 | 3745 ± 55.2 |
PK: Tmax was time to reach Cmax. If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value taken from clinical database as the difference in the time of administration and the time of the blood draw which is associated with the Cmax.
| hour | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib |
|---|---|---|---|
| PK: Time to Reach Cmax (Tmax) of Selpercatinib | 2.001 (1.50 to 3.00) | 1.999 (1.03 to 2.51) | 2.753 (2.00 to 4.00) |
PK: Apparent terminal elimination rate constant; represents the fraction of drug eliminated per unit time calculated by linear least squares regression analysis using the maximum number of points in the terminal log linear phase (e.g., three or more non zero plasma concentrations).
| 1/hour (1/h) | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib |
|---|---|---|---|
| PK: Apparent First-order Terminal Elimination Rate Constant (Kel) of Selpercatinib | 0.03122 ± 0.0094408 | 0.02607 ± 0.0054791 | 0.02562 ± 0.0040999 |
PK: Vz/F calculated as Dose/(AUC0-inf x Kel).
| Liter | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib |
|---|---|---|---|
| PK: Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Selpercatinib | 328.7 ± 156.37 | 526.3 ± 219.99 | 487.0 ± 158.59 |
Collected over Baseline up to Day 8. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 320 mg Selpercatinib | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 640 mg Selpercatinib | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 720 mg Selpercatinib | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib |
|---|---|---|---|
| PalpitationsCardiac disorders | 0/6 | 0/6 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 1/6 | 0/6 |
| DyspepsiaGastrointestinal disorders | 0/6 | 0/6 | 1/6 |
| UlcerGeneral disorders | 1/6 | 0/6 | 0/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 1/6 |
| Burning sensationNervous system disorders | 1/6 | 0/6 | 0/6 |
| HeadacheNervous system disorders | 0/6 | 0/6 | 1/6 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 0/6 | 1/6 | 0/6 |
| ErythemaSkin and subcutaneous tissue disorders | 1/6 | 0/6 | 0/6 |
| PapuleSkin and subcutaneous tissue disorders | 0/6 | 1/6 | 0/6 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib | Total |
|---|---|---|---|---|
| Mean | 37.8 ± 7.19 | 36.7 ± 10.69 | 39.3 ± 9.99 | 37.9 ± 8.91 |
| Sex: Female, Male(Participants) | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib | Total |
|---|---|---|---|---|
| Female | 1 | 1 | 3 | 5 |
| Male | 5 | 5 | 3 | 13 |
| Ethnicity (NIH/OMB)(Participants) | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 4 | 10 |
| Not Hispanic or Latino | 3 | 3 | 2 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 3 |
| White | 4 | 4 | 4 | 12 |
| More than one race | 1 | 1 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 320 mg Selpercatinib | 640 mg Selpercatinib | 720 mg Selpercatinib | Total |
|---|---|---|---|---|
| United States | 6 | 6 | 6 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Mar 2019, 1 month.
Results were first posted in May 2025, 6 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib